<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Scancell Hldgs Plc — News on 6ix</title>
<link>https://6ix.com/company/scancell-hldgs-plc</link>
<description>Latest news and press releases for Scancell Hldgs Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/scancell-hldgs-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ea4878dffbe2df12a2bf.webp</url>
<title>Scancell Hldgs Plc</title>
<link>https://6ix.com/company/scancell-hldgs-plc</link>
</image>
<item>
<title>Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/scancell-receives-fda-fast-track-designation-for-iscib1-in-advanced-melanoma-and-provides-data-update-from-its-scope-phase-2-study</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/scancell-receives-fda-fast-track-designation-for-iscib1-in-advanced-melanoma-and-provides-data-update-from-its-scope-phase-2-study</guid>
<pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
<description>Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall survival (OS) data expected in H1 2027 Initiation of the registrational Phase 3 trial with iSCIB1+ in advanced melanoma anticipated in H2 2026 OXFORD, United Kingdom, April 28, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to t</description>
</item>
<item>
<title>Scancell announces CFO transition</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/scancell-announces-cfo-transition</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/scancell-announces-cfo-transition</guid>
<pubDate>Thu, 02 Apr 2026 06:00:00 GMT</pubDate>
<description>Scancell Holdings plc announced a CFO transition with David Schilansky appointed as financial advisor and interim CFO, effective immediately, to ensure continuity as the company advances its iSCIB1+ Phase 3 trial and explores a potential US listing. Current CFO Sath Nirmalananthan will step down on April 24, 2026, and a global search for a permanent CFO is underway. Schilansky brings extensive financing expertise, including experience leading IPOs on Nasdaq and Euronext, and previously served as</description>
</item>
<item>
<title>Interim Results for the six months ended 31 October 2025</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/interim-results-for-the-six-months-ended-31-october-2025</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/interim-results-for-the-six-months-ended-31-october-2025</guid>
<pubDate>Thu, 29 Jan 2026 07:00:00 GMT</pubDate>
<description>OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its unaudited financial results for the six-month period to 31 October 2025. Highlights (including post period) DNA ImmunoBody ® iSCIB1+ (SCOPE trial): iSCIB1+, the lead product from Scancell's DNA ImmunoBody® platform, demonstrated potentially best-in-class efficacy and durab</description>
</item>
<item>
<title>Half-year Financial Report</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/half-year-financial-report-5</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/half-year-financial-report-5</guid>
<pubDate>Thu, 29 Jan 2026 07:00:00 GMT</pubDate>
<description>Scancell Holdings plc reported interim results for the six months ended 31 October 2025, with an operating loss of £8.9 million, an improvement from £10.5 million in the prior year, and a cash balance of £8.6 million. The company's lead product, iSCIB1+, demonstrated a 74% Progression Free Survival at 16 months in advanced melanoma, leading to FDA clearance for a Phase 3 trial planned to commence in 2026. Modi-1 data for head and neck and renal cell cancer is anticipated in H1 2026, and the comp</description>
</item>
<item>
<title>FDA clearance of IND application for iSCIB1+</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/fda-clearance-of-ind-application-for-iscib1</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/fda-clearance-of-ind-application-for-iscib1</guid>
<pubDate>Mon, 26 Jan 2026 07:00:00 GMT</pubDate>
<description>Scancell Holdings plc announced that the FDA has cleared its Investigational New Drug application for a Phase 3 trial of iSCIB1+ in advanced melanoma, with progression-free survival as the endpoint. Data from the 140-patient SCOPE Phase 2 trial showed iSCIB1+ achieved a 74% progression-free survival rate at 16 months in the target population, a 24-percentage point improvement over the current standard of care. The company plans to start the registrational Phase 3 trial in 2026 and is exploring f</description>
</item>
<item>
<title>Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/scancell-announces-fda-clearance-of-ind-application-for-global-phase-3-trial-of-iscib1-in-advanced-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/scancell-announces-fda-clearance-of-ind-application-for-global-phase-3-trial-of-iscib1-in-advanced-melanoma</guid>
<pubDate>Mon, 26 Jan 2026 07:00:00 GMT</pubDate>
<description>Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in progression free survival (PFS) over real world SoC and historic controls NOTTINGHAM, United Kingdom, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) h</description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/notice-of-results-47</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/notice-of-results-47</guid>
<pubDate>Thu, 22 Jan 2026 07:00:00 GMT</pubDate>
<description>Scancell Holdings plc will announce its interim financial results for the six months ended 31 October 2025 on Thursday, 29 January 2026, and will also provide a business update. The company, which develops active immunotherapies for cancer, will host a live webcast for analysts and investors at 14:00 GMT on the day of the results. This announcement is a notice of upcoming financial reporting and an investor presentation, with no specific financial figures for the interim period yet disclosed.
</description>
</item>
<item>
<title>Continued improvement in PFS with iSCIB1+</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/continued-improvement-in-pfs-with-iscib1</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/continued-improvement-in-pfs-with-iscib1</guid>
<pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
<description>Scancell Holdings plc announced updated Phase 2 data for its iSCIB1+ immunotherapy in advanced melanoma, showing a progression-free survival (PFS) of 74% at 16 months, significantly outperforming the standard of care's 50% PFS at 11.5 months. Early overall survival data also indicates a 14% improvement at 26 months over standard of care. The company has received positive regulatory advice and is advancing iSCIB1+ into late-stage registrational trials, targeting 80% of melanoma patients based on </description>
</item>
<item>
<title>Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/scancell-updated-phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iscib1-in-patients-with-first-line-advanced-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/scancell-updated-phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iscib1-in-patients-with-first-line-advanced-melanoma</guid>
<pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
<description>Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population for late-stage development Early overall survival (OS) data, most advanced for SCIB1, showing a 14% improvement at 26 months over SoC1 In advanced planning for registrational trials with positive scientific advice from regulators To hold late-breaking oral presentation on SCOPE t</description>
</item>
<item>
<title>Research Update</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/research-update</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/research-update</guid>
<pubDate>Fri, 07 Nov 2025 07:00:00 GMT</pubDate>
<description>Scancell Holdings Plc announced positive Phase 2 data for its iSCIB1+ Immunobody® DNA active immunotherapy in late-stage melanoma, presented at SITC 2025. The SCOPE trial demonstrated an 11-month progression-free survival (PFS) of 78% in the target population, significantly exceeding the historic 12-month PFS of 46% for doublet checkpoint therapy. Furthermore, combined data for the HLA target population showed a 22-month PFS of 69%, alongside superior overall response and disease control rates w</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/result-of-agm-146</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/result-of-agm-146</guid>
<pubDate>Thu, 30 Oct 2025 15:30:00 GMT</pubDate>
<description>Scancell Holdings PLC announced that all resolutions proposed at the Annual General Meeting held on October 30, 2025, were duly passed. The company is focused on developing targeted off-the-shelf active immunotherapies. Their lead product from the DNA ImmunoBody platform, iSCIB1+, has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy and additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immuno</description>
</item>
<item>
<title>Notice of AGM</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/notice-of-agm-52</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/notice-of-agm-52</guid>
<pubDate>Fri, 03 Oct 2025 06:00:00 GMT</pubDate>
<description>Scancell Holdings PLC announced that its Annual Report and Accounts for the year ended April 30, 2025, along with the Notice of Annual General Meeting (AGM), will be sent to shareholders shortly. The annual report is available on the company's website at https://www.scancell.co.uk/investors/financial-info, and the Notice of AGM will be available today at https://scancell.co.uk/documents-presentations under the Annual General Meeting section. The AGM will be held on Thursday, October 30th, 2025, </description>
</item>
<item>
<title>Director Dealing</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/director-dealing-7</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/director-dealing-7</guid>
<pubDate>Tue, 16 Sep 2025 06:00:00 GMT</pubDate>
<description>Vulpes Testudo Fund, closely associated with Non-Executive Director Martin Diggle, purchased 3,150,000 ordinary shares in Scancell Holdings plc on September 12, 2025. The shares, with a value of 0.1p each, were bought at a price of 8.861 pence per share. Following this transaction, the combined holdings of Vulpes Life Science Fund and Vulpes Testudo Fund amount to 143,537,037 ordinary shares, representing 13.83% of the company's total shares.
Disclaimer*</description>
</item>
<item>
<title>Final Results</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/final-results-60</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/final-results-60</guid>
<pubDate>Thu, 11 Sep 2025 06:00:00 GMT</pubDate>
<description>Scancell Holdings reported its business update and financial results for the year ended April 30, 2025. The company's operating loss was £15.0 million, compared to £18.3 million in the previous year. The group's cash balance at year-end was £16.9 million, up from £14.8 million. A financing in late 2024 raised gross proceeds of £11.3 million. A second commercial license with Genmab for SC2811 secured $6 million in total upfront payments and up to $630 million in potential milestones and low-singl</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/directorpdmr-shareholding-176</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/directorpdmr-shareholding-176</guid>
<pubDate>Mon, 04 Aug 2025 09:23:00 GMT</pubDate>
<description>Director/PDMR Shareholding.</description>
</item>
<item>
<title>Strong Phase 2 data on iSCIB1+ in Melanoma</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/strong-phase-2-data-on-iscib1-in-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/strong-phase-2-data-on-iscib1-in-melanoma</guid>
<pubDate>Tue, 22 Jul 2025 06:00:00 GMT</pubDate>
<description>Strong Phase 2 data on iSCIB1+ in Melanoma.</description>
</item>
<item>
<title>Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/scancell-reports-phase-2-data-showing-strongly-improved-outcomes-in-late-stage-melanoma-with-its-immunobodyr-iscib1</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/scancell-reports-phase-2-data-showing-strongly-improved-outcomes-in-late-stage-melanoma-with-its-immunobodyr-iscib1</guid>
<pubDate>Tue, 22 Jul 2025 06:00:00 GMT</pubDate>
<description>SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly exceeding the 48-50% for standard of care 12-month progression-free survival also markedly improved, with a 20% increase over standard of care iSCIB1+ Immunobody® selected for future development; planning for registrational Phase 2b/3 global stu</description>
</item>
<item>
<title>Share Option Exercise</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/share-option-exercise</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/share-option-exercise</guid>
<pubDate>Wed, 16 Jul 2025 06:00:00 GMT</pubDate>
<description>Share Option Exercise.</description>
</item>
<item>
<title>Scancell initiates new arm in SCOPE Phase 2 study</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/scancell-initiates-new-arm-in-scope-phase-2-study</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/scancell-initiates-new-arm-in-scope-phase-2-study</guid>
<pubDate>Wed, 25 Jun 2025 06:00:00 GMT</pubDate>
<description>Scancell initiates new arm in SCOPE Phase 2 study.</description>
</item>
<item>
<title>Investor Update via Investor Meet Company.</title>
<link>https://6ix.com/company/scancell-hldgs-plc/news/investor-update-via-investor-meet-company</link>
<guid isPermaLink="true">https://6ix.com/company/scancell-hldgs-plc/news/investor-update-via-investor-meet-company</guid>
<pubDate>Tue, 22 Apr 2025 06:10:00 GMT</pubDate>
<description>Investor Update via Investor Meet Company..</description>
</item>
</channel>
</rss>